Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Nov 7;202(9):1159-62.
doi: 10.1084/jem.20051224.

Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity

Matthias G von Herrath  1 , Gerald T Nepom
Affiliations

Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity

Matthias G von Herrath et al. J Exp Med. .

Abstract

Induction of selective, autoantigen-specific tolerance is the "holy grail" for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical Immunological Societies (FOCIS) Meeting, May 12-16, 2005, in Boston, MA, a Kirin-sponsored "Ideashop" was convened to discuss this theme amongst scientists, clinicians, industry partners, and funding agencies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A translational roadmap for academic researchers.
See this image and copyright information in PMC

References

    1. Diabetes Prevention Trial—Type 1 Diabetes Study Group. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346:1685–1691. - PubMed
    1. Bregenholt, S., M. Wang, T. Wolfe, A. Hughes, L. Baerentzen, T. Dyrberg, M.G. von Herrath, and J.S. Petersen. 2003. The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes. Scand. J. Immunol. 57(5):432–438. - PubMed
    1. Bergerot, I., N. Fabien, A. Mayer, and C. Thivolet. 1996. Active suppression of diabetes after oral administration of insulin is determined by antigen dosage. Ann. NY Acad. Sci. 778:362–367. - PubMed
    1. Bielekova, B., B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J.A. Frank, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6(10):1167–1175. - PubMed
    1. Kappos, L., G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, and L. Steinman. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6(10):1176–1182. - PubMed

Publication types